Roche reports positive follicular lymphoma data for Gazyva/Gazyvaro

Roche has announced new findings from the phase III trial GALLIUM that demonstrates the safety and efficacy of Gazyva/Gazyvaro in the treatment of follicular lymphoma.

A new analysis of data from the pivotal study, which assessed the performance of the therapy in people with previously untreated follicular lymphoma, showed that Roche's therapy was able to deliver prolonged benefits.

Improvements in progression-free survival with Gazyva/Gazyvaro-based treatment compared to MabThera/Rituxan were sustained over a further six months of follow-up, irrespective of chemotherapy regimen.

In addition, health-related quality of life as reported by people in the Gazyva/Gazyvaro treatment group improved from the baseline assessment, showing the treatment's effectiveness in addressing lymphoma-related symptoms without a major risk of side effects.

Additional preliminary analyses from this study supported the potential use of positron emission tomography as an early predictor of progression-free survival and overall survival in untreated follicular lymphoma.

Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "This data adds to the growing body of evidence that Gazyva/Gazyvaro plays an important role in advancing the treatment of follicular lymphoma."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.